Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.

Blood·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

Cancer cell·2026
Same author

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Blood·2026
Same author

Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease.

Biomolecules·2025
Same author

Highly specific intracellular ubiquitination of a small molecule.

Nature chemical biology·2025

Related Experiment Video

Updated: Jun 3, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Tanespimycin as antitumor therapy.

Meletios-Athanassios Dimopoulos1, Constantine S Mitsiades, Kenneth C Anderson

  • 1Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece. mdimop@med.uoa.gr

Clinical Lymphoma, Myeloma & Leukemia
|April 2, 2011
PubMed
Summary

Tanespimycin shows promise as a novel treatment for relapsed/refractory multiple myeloma (MM). Further trials will clarify its role in MM and other cancers like breast cancer.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Heat shock protein 90 (HSP90) is crucial for cancer cell survival and proliferation.
  • HSP90 inhibitors, like tanespimycin, disrupt these processes, offering potential antineoplastic effects.
  • Tanespimycin, an HSP90 inhibitor, has been investigated for various malignancies.

Purpose of the Study:

  • To review the efficacy of tanespimycin in solid tumors and multiple myeloma (MM).
  • To evaluate tanespimycin's role in monotherapy and combination regimens.
  • To assess tanespimycin's potential in treating relapsed/refractory MM and breast cancer.

Main Methods:

  • Literature review of published papers and conference abstracts up to October 2009.
  • Analysis of Phase I clinical trial data for tanespimycin in solid tumors and MM.
  • Evaluation of response rates in monotherapy and combination therapy arms.

Main Results:

  • Tanespimycin monotherapy showed no response in metastatic melanoma.
  • Combination therapy with trastuzumab in metastatic breast cancer yielded a 24% partial response rate.
  • In multiple myeloma, single-agent tanespimycin demonstrated activity, with 27% achieving minor response or better when combined with bortezomib.

Conclusions:

  • Tanespimycin is a promising agent for relapsed/refractory multiple myeloma.
  • Ongoing trials are crucial to define tanespimycin's therapeutic role in MM and other cancers.
  • Tanespimycin warrants further investigation, particularly in combination therapies for breast cancer and MM.